Sign in to view content

TIE2, VEGF, and Integrin Receptor Interplay and its Role in Retinal Disease

Peter K. Kaiser, MD FASRS

Video
Published 2020

Related

New Biosimilar Bevacizumab and Ranibizumab for Retinal Diseases
Alay S. Banker, MD
Annual Meeting Talks
2018
Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Annual Meeting Talks
2018
Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024

Category: AMD-Neovascular

See more